Clinical trials: Nonalcoholic Fatty Liver
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Non-Alcoholic Steatohepatitis
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT04378010
- Testing
- EDP-305 1.5 mg, EDP-305 2 mg
- Where
- 81 sites in United States, Argentina and 4 more
- Volunteers
- 98 people
- Sponsor
- Enanta Pharmaceuticals, Inc
NAFLD, NASH
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT06410924
- Testing
- DD01
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neuraly, Inc.
NASH - Nonalcoholic Steatohepatitis
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
This is a Phase 1, open-label, drug-drug interaction (DDI) study of pemvidutide (ALT-801) under steady state conditions on concomitantly administered medications in healthy subjects.
- Trial name
- NCT04972396
- Testing
- Pemvidutide, Metformin, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Obesity, Morbid, Non-Alcoholic Fatty Liver Disease
The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease. In the absence of chronic alcohol abuse or other liver diseases, NAFLD incorporates a wide spectrum of liver pathologies and is defined…
- Trial name
- NCT01619215
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 35 people
- Sponsor
- King Saud University
NAFLD - Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Hepatic and Cardiac Metabolic Flexibility in Subjects With T2DM With and Without NAFLD
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis.
- Trial name
- NCT04698486
- Testing
- Hyperinsulinemic euglycaemic clamp
- Where
- Denmark
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis
A double-blind placebo controlled randomized Phase 2 study to determine if JKB-122 compared with placebo resolves NASH on liver biopsy and improves fibrosis
- Trial name
- NCT04255069
- Testing
- Dose 1 JKB-122, Dose 2 JKB-122
- Volunteers
- 300 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Non Alcoholic Fatty Liver, Hepatitis B
Combi-elastography Assessment of Chronic Liver Disease Multi-center Study
HITACH developed a new combi-elastography imaging technology combines shear wave imaging and strain imaging technology. In the study, not only the F index which is related to the stage of liver fibrosis can be obtained, but also…
- Conditions
- Non Alcoholic Fatty Liver, Hepatitis B, Drug-induced Liver Injury
- Trial name
- NCT04625166
- Where
- China
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
HIV, HIV-Infections
The Visceral Adiposity Measurement and Observation Study
The Visceral Adiposity Measurement and Observation Study
- Conditions
- HIV, HIV-Infections, HIV-1-infection, HIV I Infection
- Trial name
- VAMOS (NCT05383456)
- Testing
- Diagnostic Test, HIV Anti-retroviral Background Therapy
- Where
- 8 sites in United States
- Volunteers
- 196 people
- Sponsor
- Theratechnologies
NAFLD
Effect of Consumption of Millet Diet in Patients With NAFLD
With NAFLD fast rising its ranks in becoming a major non communicable disease in India and across the globe, this study aims at primary prevention of the condition.
- Trial name
- NCT06341790
- Testing
- jowar based products
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-alcoholic Fatty Liver Disease
To Explore the Effectiveness of Jing-Si Herbal Tea Against Non-alcoholic Fatty Liver Disease
The aim of this study is to explore the effectiveness of Jing-Si Herbal Tea on improving the Non-alcoholic fatty liver disease patients
- Trial name
- NCT05858138
- Testing
- Jing-Si Herbal Tea
- Where
- Taiwan
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Taichung Tzu Chi Hospital
Fatty Liver
Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
Background: Non-alcoholic fatty liver disease (NAFLD) affects 30% of the Asian adult population and is emerging as one of the important leading causes of liver cancer and cirrhosis.
- Trial name
- NCT06203548
- Testing
- Lifestyle modification programme
- Where
- Hong Kong
- Volunteers
- 150 people
- Sponsor
- Chinese University of Hong Kong
Non Alcoholic Fatty Liver
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
assessment of NAFLD among diabetic, pre-diabetic and non diabetic participants Using Non Invasive Methods.And correlation between lab and radiological methods .
- Trial name
- NCT04553796
- Testing
- fibroscan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
This study aims to identify the effect of adding TENS to the Mediterranean diet on appetite and liver enzymes in Nonalcoholic fatty liver patients.
- Trial name
- NCT07200934
- Testing
- Transcutaneous electrical stimulation (TENS), Mediterranean Diet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Liver Disease, Fatty Liver
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Background: Metabolism refers to the many chemical pathways by which various compounds, including food, are processed and used in the body.
- Trial name
- NCT02520609
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease (NAFLD)
Anti-LPS Antibody Treatment for Pediatric NAFLD
The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver…
- Trial name
- NCT03042767
- Testing
- IMM-124E
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Miriam Vos, MD
NAFLD
Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease Patients
Non-alcoholic fatty liver disease (NAFLD) includes a wide range of disorders that consist of simple fatty infiltration, steatohepatitis (NASH), and end-stage liver disease (cirrhosis).
- Trial name
- NAFLD (NCT04834063)
- Testing
- Serum Zinc a level, serum selenium level, Fibroscan measurement
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Nonalcoholic Fatty Liver Disease
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease in the United States. The incidence of NAFLD is very similar to that of obesity, type 2 diabetes, and the metabolic syndrome.
- Trial name
- NCT00983463
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Vanderbilt University
Non-alcoholic Steatohepatitis
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05766709
- Testing
- NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.